Procyrion Announces CEO Transition, Appointing Jason Whiting as New CEO

PR News WireThis post was originally published on this site

Share this story

Eric S. Fain, MD to retire after more than eight years as CEO, will remain on Board of Directors

HOUSTON, Nov. 17, 2026 /PRNewswire/ — Procyrion®, Inc., a medical device company developing the novel Aortix® system designed to improve outcomes for patients with cardiac and renal impairment, announced today the appointment of Jason Whiting as President and Chief Executive Officer, succeeding Eric S. Fain, MD, who had served in the role since 2018. Dr. Fain has announced his plans to retire and will remain on Procyrion’s Board of Directors to support the company’s transition from clinical-stage to commercial-stage.

Procyrion’s DRAIN-HF pivotal trial of its Aortix percutaneous mechanical circulatory support (pMCS) device continues to enroll patients with acute decompensated heart failure (ADHF) who remain congested despite standard medical therapy, a condition known as cardiorenal syndrome (CRS). The trial also includes a registry arm for patients with end-stage heart failure (HF) whose persistent congestion and poor renal function place them at high risk to receive a left ventricular assist device (LVAD) or heart transplant.

“On behalf of the Board, I want to thank Eric for more than eight years of exceptional leadership,” said Gary Burbach, Chairman of the Board of Procyrion. “Eric led the team to advance Aortix from prototype to a durable, robust design, which is now a Breakthrough-designated therapy in a pivotal trial. As DRAIN-HF progresses, the Board conducted a deliberate succession process to identify a leader with the commercial experience to guide Procyrion’s next phase. We are confident Jason is the right person to lead Procyrion’s team forward to complete our clinical trial activities, gain regulatory approval and prepare Aortix for market.”

“Patients with diuretic-resistant heart failure have few treatment options, and I am proud of what this team has achieved on their behalf,” said Dr. Fain. “I remain committed to Procyrion’s mission to bring this exciting technology to a broad range of heart failure patients and look forward to partnering with Jason as a member of the Board.”

Mr. Whiting brings more than 25 years of medtech experience commercializing novel technologies, from implantable and wearable devices to capital equipment, including several therapies for patients with heart failure. Most recently, he served as CEO of Avation Medical, a medical device company advancing a wearable neuromodulation therapy for overactive bladder. During his tenure, he implemented a new commercial strategy, built a commercial payer reimbursement program and closed a Series D financing within 18 months. Previously, he served for more than eight years as President of ZOLL Cardiac Management Solutions, following his role as Vice President of Global Marketing and Clinical Operations. Mr. Whiting holds an MBA from Michigan State University and a BBA from the University of Michigan.

“I am honored to join Procyrion at such an important point in the company’s journey,” said Mr. Whiting. “Eric and the team have built a truly differentiated catheter-based technology with the potential to transform care for patients suffering from heart failure and kidney disease, supported by compelling early clinical data. My priorities are to successfully complete enrollment in the DRAIN-HF study, advance our regulatory pathway, and establish the market access, therapy adoption, and commercialization foundation necessary for a successful launch. We have an opportunity to bring a meaningful new therapy to patients with limited treatment options, and our goal is to maximize the impact of Aortix for patients, providers, and healthcare systems.”

About Procyrion
Procyrion®, Inc. is a privately held medical device company dedicated to providing effective treatment options for patients with cardiac and renal impairment. The company is developing the Aortix® percutaneous mechanical circulatory support device, a catheter-deployed pump technology that uniquely harnesses fluid entrainment to pump blood to address multiple conditions with significant unmet needs. Aortix is limited by Federal law to investigational use only and is not approved for sale in any geography. Please visit www.procyrion.com for more information.

Cautionary Statement Regarding Forward-Looking Statements
This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not a guarantee of future performance.

SOURCE Procyrion

Leave a Comment

Your email address will not be published. Required fields are marked *

*